VEGFA and retinopathy of prematurity: Recent studies have shown that anti-VEGF agents, such as monoclonal antibodies7,8, kinase inhibitors9, and soluble decoy receptors10,11, effectively inhibit angiogenesis and consequently suppress symptoms of diseases, such as ROP and cancer2.